but pharma is ready for a reinvention.ompanies like novartis, large company, approaching cancer in a very special way, targeted therapies, gene-based approaches and they're going to make a big difference. people like david epstein that runs the pharmaceutical business at novartis, he knows the business and going after that area. so i will still watch for the top people. >> one last question, does it work for every industry? we've got turnarounds we're following, blackberry jc penney, these seem like really difficult turn arounds. could you get in there and change? >> this book is meant for all industries. >> right. >> it really does work. it always starts with people, comes up with culture and ends with execution. if you have these three legs of the stool, it's going to work. but the ceo has to make the people part work, the culture work and the execution. >> tougher than most people can handle, fred. >> it's tough. >> most people can't do it. >> and that's why looking for great ceos is critical. >> absolutely. that's fred

why is big pharma struggling here?he biogens, the gileads doing all the inventing? >> reinvention is what i talk about in the book. i think there's a need for big pharma to reinvent, because some of these older approaches are no longer working. you just heard today, and i think your channel is carrying the news, a new drug for ms, biogen is the company, specialty products are the new way people want to have their drugs come to them. the primary drugs are starting to get a little old. >> right. >> so those that embrace specialty pharma do a lot better. also, your r & d, you've got to take that research and development engine seriously. if you spend your time as ceo doing a lot of other things, probably you're not focusing on the most important thing. but pharma is ready for a reinvention. and there are companies like novartis, large company, approaching cancer in a very special way, targeted therapies, gene-based approaches and they're going to make a big difference. people like david epstein that runs the pharmaceutica

big pharma companies have passed the baton to the biotech.elgene has the breakthrough drugs in the pipeline. all week we are going to reveal the best new drug companies in the world. do not move. lightning round's next. >> it is time, it is time for the lightning round. cramer takes rapid-fire calls and i tell you whether to buy, buy, buy or sell, sell, sell. we play to this sound and then the lightning round is over. are you ready, skee-daddy? time for the lightning round. i'd like to start with lee in california. >> caller: hey, jim. sunny boo-yah from california. >> i wish i were there what's going on? >> caller: in view of the turnaround in the housing industry, i feel that the more than new houses, the more new lawns, the more new lawns, the more new lawn mowers, what is your opinion of the briggs and stratton corporation? >> i think that is a terrific buy. that's been one of our highly recommended stocks since superstorm sandy. ian in florida. >> caller: hallandale beach booyah to ya. i held the position of avy for the last five years.

big pharma companies passed the baton to the biotech.elgene has the breakthrough drugs in the pipeline. all week we are going to reveal the best new drug companies in the world. do not move. lightning round's next. ♪ ♪ i don't want any trouble. i don't want any trouble either. ♪ [ engine turns over ] you know you forgot to take your mask off, right? [ siren wailing in distance ] ♪ [ male announcer ] introducing the all-new beetle convertible. now every day is a top-down day. that's the power of german engineering. it's lots of things. all waking up. connecting to the global phenomenon we call the internet of everything. ♪ it's going to be amazing. and exciting. and maybe, most remarkably, not that far away. we're going to wake the world up. and watch, with eyes wide, as it gets to work. cisco. >>. >> it is time, it is time for the lightning round. cramer takes rapid-fire calls and i tell you whether to buy, buy, buy or sell, sell, sell. we play to this sound and then the lightning round is over. are you ready, skee-daddy? time for the li

how about a big pharma company with a big 3.9% yield?ter than treasuries after the tax benefits. it's been left behind by the rest of its cohort. i can't believe i'm talking about this one because it's so far behind. i'm talking about one of the great american companies, merck, mrk, the pharmaceuticals giant that's stumbled more times in the last few months than a college kid on st. paddy's day. since early december, the early pharma names have roared. pfizer up 12%, bristol miers up. i'm typical of my eighth anniversary, i somehow got blue ink on my hand. and cell gene jumped 43%. meanwhile, merck has done nothing. it's actually down about 1% over the same period. right now there are reasons merck has underperformed the rest of the ones. in december, the good -- in december, the company got bad clinical trials from a new cholesterol drug that they were working on. and i thought it was going to be a big one, i have to tell you. so merck decided to stop development here in the u.s. and pull the drug overseas where it was already approved.

gilead the company reminds me of the big pharma outfits in the 1990s heyday.ould come to work each day, up at 6:00, then up to 3:00, then closed for the weekend. didn't trade saturday, opened up ten on monday. check out the chart in '87. anyway, gilead's got a robust pipeline and a potentially game-changing hepatitis-c drug, could get fda approval in the near future. yet gilead the stock grows like the slow-growing names we're familiar with in pharma today. actually, it's cheaper even though it's a rapidly growing biotech. this stock may have room to run and i think deserves to go much higher. chris in california. chris? >> caller: hey, jim. i've been watching mankind corporation's stock for a while. they've had some great medical products in the past and they're currently awaiting fda approval for an insulin delivery system that would eliminate injections. do you have any thoughts here? >> yeah, it's a serve mankind, it's a cookbook. no, i don't want you in mankind. i'm talking about the highest level kind of drugs here. i'm talking about bristol-myers, gilea

consumer products and big cap pharma.ust a big cap pharma, and i'm going to go with bristol myers myers. goldman sachs think they're going to double their earnings by the end of the decade, and so do i. >> josh brown. >> in an amazing group think, i'm going to reiterate pfizer. closed at at 52 week high. i don't think she's close to being done. >> anthony, break the trend. >> mastercard here. look for a share repurchase and an increase in the dividend. this stock's got a lot

they'd rather take the money from big pharma then put their lower priced drugs on the market they're the ones who are saying you can't pay me enough that i will hurt low income people by not putting this low cost me out of the barn that a crime is being committed no i'm not i'm just saying are wrong is being done well i'm saying if there is a wrong is in your view i would think you would take say how can these generics both of them up and if you think about profit over helping they're the ones who hold the generics that can help low income people and they're the ones who are more interested in big pharma as money than helping low income people and i would think that's the cycle beyond and i hear i hear sort of a course of saying i think this room on this is borderline collusion because you have two firms who are you know close the competitors they were going to sort of work together to fix the price because it is sort of a price fixing scheme when you tell the company i'm going to pay you so that our price can stay all abated and your lower price your lower priced good came into the

but we know what made the big pharma companies so hot in the '90s.were constantly innovating, developing major new drugs, bountiful pipelines, and we can use that template to find the stocks of the next big drug companies, the ones that deserve to trade the way merck and eli lilly and pfizer did in the 1990s. and that is why all week we've been highlighting the larger biotech plays, companies with terrific prospects like celgene and gilead. right now, they're the ones doing the innovating. and tonight i've got a new one for you, and that stock is biogen idec, biib. it's a major biotech that hit a new 52-week high today and $183 as the stock soared $5.60, up more than 3% after the fda approved their new multiple sclerosis drug. don't be scared away. it's had a rally since i recommended it last january at $117, when everybody i know thought it was already too high, and it's given you a 56% gain. but please, remember the analogy here. back in the '90s when the stocks were on fire, they would run and run some more and run some more year after year. bioge

gilead, the company, reminds me of the big pharma outfits in their 1990s heyday. come in every day, merck would be up 6 and then 3 and then 7 and then close for the weekend. what can you do, didn't trade saturday. opened up 10 on monday. yeah, check out that chart in '86, '87. gilead has a robust pipeline and a potentially game-changing hep c drug. gilead the stock has slow-growing names that we're familiar with pharma today, cheaper, even though it's a rapidly growing biotech. this stock may have room to run. i think it deserves to go much higher. chris in california. chris. >> caller: hey, jim. i've been watching mankind corporation stock for a while. they've had some great medical products in the past and they're currently awaiting an fda approval for an insulin delivery system that would eliminate injections. any thoughts here? >> yeah, to serve mankind, it's a cookbook. no, i don't want you in mankind. i'm talking about the highest level kind of drugs here. i'm talking about bristol-myers for dividend and gilead for growth. we don't need to go down the food c

. >> john: the real reason you'll never see in our lifetime is it is such a big threat to pharma. >> also to alcohol. people want to get high. people want to get drunk. pot doesn't have a lobby. >> when pot is legal -- >> they keep forgetting to show up. >> and when pot is legal it lobbying pharma that ends up boning all of the fields. you may not believe this but there was a guy on fox business channel yesterday who was talking about the business of pot. on fox business. >> john: once they buy it, they can call it a drug. >> big pharma. >> if they can spray it, they can genetically engineer it.% >> they can put it in our corn and they can never tell us. >> we could have like fish pot. >> i can't wait. if you're allergic to fish, just die and you won't even know it. >> john: why is it only ron paul and rand paul leading the fight politically on this issue? think about it. >> i think the liberals tired out. now it is happening without them. >> the government reflect the people at all in anything anymore? >> john: it would help with our taxes and that's where we get the expression join

we do big pharma, we don't pay. tax cuts, we don't figure what it's going to do to the economy, but you, you might have to pay for it. there is one senator prepared to filibuster to protect social security, medicare and medicaid. senator bernie sanders will join me in a moment, but president obama, he went to capitol hill today for a closed door meet wg the democrats. senate budget chairwoman patty murray, she revealed a plan with new revenue and spending cuts. nearly $1 trillion over the next ten years. president obama will meet with both parties on capitol hill. meanwhile, chairman paul ryan unveiled his budget plan and listen to how ryan describes republican priorities. >> the most important question isn't how we balance the budget, but why. a budget is a means to an end. an end is the well being of the american people. >> the most important question is how we balance the budget and making sure it's not on the backs of working americans. congressman ryan also made an unfortunate slip. >> this to us is something w

>>> okay, all week we are profiling the real growth pharmas. i think pharma is a real interesting spot here. why? because the old ones yield great. the new ones are growing so fast and yet they're not that expensive versus even terrific companies like general mills, like kellogg. we are in the sweet spot looking for big stocks in the out years all week. stay tuned. there is always a bull market somewhere. i promise to try to find it just for you. i'm jim cramer. see you tomorrow! >>> welcome to today's "worldwide exchange." details on the cyprus bailout, the finance minister says the tax on deposits above 100,000 euros could be in the region of 40%. he's also vowing banks will reopen on thursday. stockses are trying to recover. the head of the euro group backtracking after his comments regarding the cyprus temporary plate. said markets are in something of a tailspin. >>> fresh data out today and u.s. home prices could show the sector continuing to claw its way back from recovery. jay you're watching "worldwide exchange," bringing you business n

. >> reporter: aarp and the ama argue settlements allowing big pharma companies which pay companies towait, undermine abilities for doctors to give cost-effective prescriptions to patients. analysts from deerfield institute found generics lost 52% of them. armen . >> these deals have been structured such that generics will get on the market before the patent expires that the brand name company is protecting. >> reporter: the justices had tough questions from both sides during today's hearing. a decision is expected by late june. i'm bertha combs. >> here's jeff brennan, currently a partner at mcdermott. the simple question, i guess is, who's winning and who's losing here? are consumers losing? are drug companies winning? >> it's really not that simple. it depends on your view about that paradigm which the ftc is challenging. they would say, and their supporters, would say that in a settlement agreement in which the innovator company pays money to the generic, that that has an effect where generics enter the market at a lower price, and consumers are worse off because they don't have an

. >>> okay, all week we are profiling the real growth pharmas. i think pharma is a real interesting spot here. why? because the old ones yield great. the new ones are growing so fast and yet they're not that expensive versus even terrific companies like general mills, like kellogg. we are in the sweet spot looking for big stocks in the out years all week. stay tuned. there is always a bull market somewhere. i'm jim cramer. see you tomorrow! >>> good evening, everyone. i'm larry kudlow. this is "the kudlow report." is famed neurosurgeon ben carson the black conservative who can save the gop. he retires in 100 days and will reveal his plans for future public service to us in just a few moments. >>> and government payroll has dropped 37,000 since the recession bottom, but private jobs have rocked 5.2 million higher. as i've said many times, lower spending and limited government, including government jobs, is good for the private economy. that is the real engine of the economic prosperity. >>> plus the supreme court this week will hear two important

there's lots of news in pharma, biotech and so on and also lots of news elsewhere in health.prised it's taken off like this. >> even today, if you look at pharma stocks, a number of them hitting 11 1/2 year highs, whether bristol-myers, lily, jng. your top holding is roche, gilead, sanofi and merck. why can the gains in those continue to go? >> you're going to keep seeing some of that. we can go through a variety of issues. the hot thing right now is we're heavily invested in roche for their cancer position. about june 1st, however, you have coming up something called the american society of clinical oncology meetings. so it's a big meeting where all the news on cancer drugs comes out. so we've got our playbook all set together. roche is a star, and bristol-myers is a star. look at the chart on bristol, it's been going up. we expect it to continue to move really nicely. >> yeah, talk to me about, you know, name like gilead. >> gilead is, you know, not an asco stock so much, but it's a great play on anti-virals. it's one of the biggest, or the biggest large profitable biotech

and i think pharmas will be do very well. big pharma, as well as specialty, because they have intellectual cap, they're creating new drugs, and i think they'll add wealth to the shareholder in the next year or two. >> very good. thank you all. nice to see you. appreciate it very much. >> thank you. >>> we have some breaking news right now on wells fargo. what's up? >> bill, wells fargo is confirming that their website has apparently been attacked by hackers in what's commonly known as a denial of service attack. wells says that the vast majority of their customers have not been affected and the customer information there, it's safe. but that many stomn fact, are having difficulty accessing the site as a result of this presumptive attack on wells fargo. they say the disruption is intermittent and they're advising customers who want to get into their wells accounts to try logging in again, ie, repeatedly, and hope that you can get in that way. but, again, confirming that their website, if you've been having trouble getting in,

. >> two dow component pharma stocks headed in opposite directions. continuing the okay to continue the safety and effectiveness of vytorin as the cholesterol-busting treatment. this made by pfizer can cause fatal irregular heart rhythm. merck gained 3% on the day while pfizer lost ground. >>> president obama's nominee to chair the securities and exchange commission says she'll be an investor advocate. mary jo white questioned by senators at her confirmation hearing this morning said that if confirmed the american public would be her client and that she would not back off if there was any evidence of wrongdoing at major institutions. >> assuming you found wrongdoing, i think you'd proceed quite vigorously against effectively anyone that you find evidence of wrongdoing on, but certainly financial institutions at the sec, which of course, doesn't have the criminal powers, those consequences are not taken into account before charging decisions are made so that the sec, there's no institution too big to charge. >> white is expected to get the okay for tha

johnson & johnson also part of the nyse pharma index and that index hit its highest level in almost 12 years today. here are some other top performers in that group. bristol-myers squibb leading the way up almost 25% year to date, followed by eli lilly, pfizer, amgen and merck. >>> it is set to become one of the ten largest shareholders in goldman sachs. the move comes as goldman gives berkshire millions of shares in place of warrants dating back to the depths of the financial crisis and that's when buffett came to the rescue of the wall street firm by investing $5 billion. goldmaniay stock was closing at their 146. at that price berkshire would receive 9.5 million shares. netflix was the biggest gainer in the s&p 500 today after an analyst boosted the company's price target to $225. he says the company's streaming video business has the potential of drawing in more subscribers. netflix shares have doubled this year and they rose today to $190 and that's a gain of 5.5%. >> a historic hearing on the u.s. supreme court on whether same-sex couples would have time to rally. john harwood jo

pharma company trying to hold off a takeover, offering shareholders 20% of the royalties on its multiple sclerosis drug. shares rose better than 3%. >>> tonight nbr kicks off a week-long series called "in focus, the american recovery." the key question to paraphrase the late new york mayor ed koch, how are we doing? here's carl quintanilla with a look at what's going right in the economy and what's not. >> reporter: that sound you hear is the american economic recovery at its sweetest. the hammers and drills of the housing market. across the country, the median price of a home is up 7% in just the past year. sales of existing homes are at multi-year highs. since housing is about 1/5 of gdp, it may be the best thing we have going. >> as the housing starts to bottom and recover, at the end of the day americans have more of their net worth in their house than any other asset. and this is a huge part of the confidence, rebuilding of confidence. >> reporter: housing is one of three pillars that are responsible for the recovery as we know it. autos is another. the revitalization of the big thr

any fast track to this stuff and open up a new highway to the international space station andrey pharma. kazakstan. more news in half an hour. you know sometimes you see a story and it seems so you think you understand it and then. you hear or see some other part of it and realize everything. is a big. wealthy british. market. find out what's really happening to the global economy with. no holds barred look at the global financial headlines to conjure reports. good lumber tour to. build a new. mission to teach me. this is why you should care only. this is the kaiser report if you're playing a poker game and you're look around the table and. it's you if you're negotiating a bailout for your national banking system and you look around the or the troika in this case and you can't.

coming to you live from moscow with me andrew pharma. now the world has got to hey the voice of whistle blowing u.s. soldier bradley manning for the first time since his imprisonment in twenty ten in a recording leaked despite a court than he explains why he released classified military data he says he wanted the world to see the true cost of war accusing troops of not valuing human life and comparing them to children torturing and with a magnifying glass. tom barton gave me some details on the case. he used emotive languages especially as he worked through this over an hour of audiophiles statement to the court describing his feelings we've taken a couple of edited excerpts of that one of them concerns this video from the cockpit of an apache attack helicopter over iraq the two pilots very eager to engage a group of what turned out to be civilians on the ground killing twelve of them including two reuters journalists a van then comes to try and help those shot in the first burst of firing and the helicopter then engages that van as well

live from moscow with me andrey pharma. venezuelans will vote on april the fourteenth to decide who will take over from the late hugo chavez the commandant enjoyed a long battle with cancer but is said to have died of a heart attack millions went on a pilgrimage to the military academy in caracas to pay their last respects to the late leader who was lying in state there's a feeling for marty's video agency was also there. vice president nicolas maduro sworn in as the president and so elections take place some voices in the opposition notably the man who is the main opposition. who have called the swearing in as. hugo chavez personally appointed. as the man that he wanted to succeed him and of course hugo chavez the late president has immense popularity and that is why you know russian f.m. has said that he hopes that heritage continues to deepen the ties between russia and venezuela and he's also said that he hopes that russia will respect the outcome of venezuela and elections and he hopes that all countries around the wor

new fast track to this stuff and open up a new highway to the international space station andrey pharma kazakstan. still to go more on the life of a man who spent thirty years in prison is now lending a hand to help those who are just like him stay with us. download the official ati up locations to yourself choose your language stream quality and enjoy your favorites from alzheimer's if you're away from your television well it just doesn't matter now with your mobile device you can watch artsy anytime anywhere. when you have nowhere to live. when you don't have a family. when you have no one to ask for help you can always count on. this man is respected by criminals and also as he is a like fields out it's gone but tonight it was people like he used to be. done for the homeless on oxy. is he. just.

it could impact all pharma stocks. >> time for the close in the gold market. inflows because of the turbulence or not? >> it's been a pretty choppy session and that's a great question. mixed price action as a result of the news coming out of sigh plu prus. we but cha changed later in the afternoon. the euphoria from subsiding. we saw gold moving higher. they want to know exactly what this bail-out means. some investors disappointed from weak demand growth. and silver is actually positive today. sue, back over to you. >> thank you. to bob now. >> just off the lows. >> down by 80 now. i think the point that you were talking about, everybody wonders what happens in cyprus, does it spread to the european banks? >> when the dutch finance minister put it out, he said that cyprus was a template for europe, that implies in a bank needs to recapitalize, you go first to the bondholders and shareholders and then to your uninsured deposit holders. it's thrown a lot of people for a loop. as i have been menging, the italian bankss have been hit pretty hard. you would think

prices but billy tauzin good republican before he went off to a two million dollar your jobs at a pharma they made sure that that got put in there during the bush administration george bush happily side of the law but setting that aside this plan to turn medicare into a voucher program do you really want to say to grandma ok grandma here's your eight thousand dollars voucher and here's twenty two insurance company forms for you to fill out and be sure to remember every illness you've ever had when you were eight years old because if you get one wrought when you get sick the insurance company's going to throw you out of those three i would argue they're everyone's already drowning in paperwork anyway but now to sign up for medicare they don't give a rat's patootie what you're i know i'm just wondering why the president keeps delaying with his budget and i would argue it's because he doesn't want the american people knowing how we spending money or how the decision to say the executive branch has to propose a budget you bring to the constitution there's plenty of procedural this is a crazy